- Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.
-
Kim W
- KMID: 2447249
- Clin Mol Hepatol.
- 2019 Mar;25(1):40-41.
- doi: 10.3350/cmh.2018.0101
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C
-
Eom YW, Baik SK
- KMID: 2447248
- Clin Mol Hepatol.
- 2019 Mar;25(1):37-39.
- doi: 10.3350/cmh.2018.1011
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Recent research trends and updates on nonalcoholic fatty liver disease
-
Yoo JJ, Kim W, Kim MY, Jun DW, Kim SG, Yeon JE, Lee JW, Cho YK, Park SH, Sohn JH
- KMID: 2447244
- Clin Mol Hepatol.
- 2019 Mar;25(1):1-11.
- doi: 10.3350/cmh.2018.0037
Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease... -
- CITED
-
- Close
- SHARE
-
- Close
- Biochemical profile in an infant with neonatal hemochromatosis shows evidence of impairment of mitochondrial long-chain fatty acid oxidation
-
Bastos KL, Quaio CR, Lima FR, Araújo IM, Araújo CA, Piazzon FB, da Silva I, Benevides , Tannuri AC, Tannuri U, Azevedo RA, Kim CA
- KMID: 2447254
- Clin Mol Hepatol.
- 2019 Mar;25(1):86-91.
- doi: 10.3350/cmh.2018.0005
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Radiomics and radiogenomics of primary liver cancers
-
Jeong WK, Jamshidi N, Felker ER, Raman SS, Lu DS
- KMID: 2447246
- Clin Mol Hepatol.
- 2019 Mar;25(1):21-29.
- doi: 10.3350/cmh.2018.1007
Concurrent advancements in imaging and genomic biomarkers have created opportunities to identify non-invasive imaging surrogates of molecular phenotypes. In order to develop such imaging surrogates radiomics and radiogenomics/imaging genomics will... -
- CITED
-
- Close
- SHARE
-
- Close
- Pathologic differential diagnosis of metastatic carcinoma in the liver
-
Park JH, Kim JH
- KMID: 2447245
- Clin Mol Hepatol.
- 2019 Mar;25(1):12-20.
- doi: 10.3350/cmh.2018.0067
The liver is one of the most common sites to which malignancies preferentially metastasize. Although a substantial number of liver malignancies are primary tumors, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma,... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
-
Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato , Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H
- KMID: 2447252
- Clin Mol Hepatol.
- 2019 Mar;25(1):65-73.
- doi: 10.3350/cmh.2018.0070
BACKGROUND/AIMS: L-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively... -
- CITED
-
- Close
- SHARE
-
- Close
- Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
-
Mölleken , Ahrens M, Schlosser , Dietz J, Eisenacher M, Meyer HE, Schmiegel , Holmskov U, Sarrazin C, Sorensen G, Sitek B, Bracht T
- KMID: 2447250
- Clin Mol Hepatol.
- 2019 Mar;25(1):42-51.
- doi: 10.3350/cmh.2018.0029
BACKGROUND/AIMS: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization
-
Bannangkoon K, Hongsakul , Tubtawee T, Piratvisuth T
- KMID: 2447253
- Clin Mol Hepatol.
- 2019 Mar;25(1):74-85.
- doi: 10.3350/cmh.2018.0072
BACKGROUND/AIMS: We aimed to determine the relationship between the safety margin of an embolized area and local tumor recurrence (LTR) of patients with hepatocellular carcinoma (HCC) who underwent superselective transarterial... -
- CITED
-
- Close
- SHARE
-
- Close
- Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
-
Marascio N, Quirino A, Barreca GS, Galati L, Costa C, Pisani V, Mazzitelli M, Matera G, Liberto MC, Focà A, Torti C
- KMID: 2447247
- Clin Mol Hepatol.
- 2019 Mar;25(1):30-36.
- doi: 10.3350/cmh.2018.0061
Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs... -
- CITED
-
- Close
- SHARE
-
- Close
- Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
-
Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, Kim KI, Kim SH, Rim KS, Hwang SG
- KMID: 2447251
- Clin Mol Hepatol.
- 2019 Mar;25(1):52-64.
- doi: 10.3350/cmh.2018.0040
BACKGROUND/AIMS: Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic... -
- CITED
-
- Close
- SHARE
-
- Close
